2757results about "Antiparasitic agents" patented technology

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

Compounds or their pharmaceutically acceptable salts can modulate the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

The invention discloses a fluralamide moxidectin drop and a preparation method thereof, and relates to the technical field of veterinary drugs. The drop is prepared from the following components in parts by weight: 26 to 26.5 parts of fluralan, 1.32 parts of moxidectin, 0.10 part of butylated hydroxytoluene, 29.5 to 30.5 parts of dimethylacetamide, 19.5 to 20 parts of tetrahydrofuran polyethylene glycol ether, 13 to 13.5 parts of diethyl toluamide, 8.5 to 9.3 parts of acetone and 1.0 to 1.5 parts of ethanol. The invention has the effects of improving the stability, permeability and lasting effect of the medicine.

The invention discloses a toxoplasma gondii attenuated vaccine strain RH delta rop67 as well as a construction method and application thereof, and belongs to the technical field of parasitic disease prevention and control and biological product preparation. The attenuated vaccine strain is constructed by performing targeted knockout on the ROP67 gene in a toxoplasma gondii strain RH delta ku80 through a CRISPR / Cas9 mediated gene editing technology. Compared with a wild type strain, the attenuated vaccine strain shows remarkable attenuation characteristic and good immunogenicity. A test result shows that the attenuated vaccine strain can induce a host to generate specific immune response mainly based on cellular immunity, maintains a protection effect on toxoplasma gondii infection in a relatively long immune period, and has a protection effect on tachyzoite infection and a chronic infection stage of toxoplasma gondii strains with different virulence; the survival ability of a host to tachyzoite infection can be improved, and the formation level of cysts in tissues is reduced. The invention provides a technical scheme with long-term immune potential for research and development of toxoplasma gondii attenuated vaccines.

The invention discloses a toxoplasma gondii attenuated strain as well as a construction method and application thereof. The toxoplasma gondii attenuated strain delta MIC1 delta MIC3 disclosed by the invention is obtained by knocking out MIC1 and MIC3 genes from a TIR1 strain by utilizing a CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) technology. The toxoplasma gondii attenuated strain delta MIC1 delta MIC3 can effectively enhance macrophage functions including phagocytic ability, proinflammatory factor secretion and the like, and provides theoretical basis and technical support for clarification of an immunoregulation network of toxoplasma gondii-host interaction and development of vaccine design based on attenuated strains.

The invention relates to the field of veterinary drugs, in particular to a furalan chewable tablet and a preparation method thereof.According to the furalan chewable tablet, a coating agent with xanthan gum, gelatin and other components as main bodies is utilized, the coating performance of the furalan chewable tablet on furalan is improved, and good palatability can be provided on the basis that the whole furalan chewable tablet has good hardness, tablet preparation performance and disintegration performance; the feed is more suitable for animals to eat.

The invention relates to the technical field of medicine formulas, in particular to a fluralamide moxidectin composite drop and a preparation process thereof. The invention relates to a fluralan-moxidectin emulsion which is prepared from the following raw materials in percentage by mass: 26 to 30 percent of fluralan, 1.1 to 1.7 percent of moxidectin, 32 to 36 percent of solvent, 0.1 to 0.3 percent of butylated hydroxytoluene, 10 to 16 percent of polymer carrier and the balance of tetrahydrofuran polyethylene glycol ether. The coexisting drug is stabilized through the core-shell structure polymer carrier, phase separation is prevented, a neutral environment is maintained, long-acting stability is ensured, the transdermal absorption rate is optimized, skin irritation is reduced, and the synergistic drug effect is improved. Meanwhile, the slow release period of the medicine is prolonged, the metabolic interference and accumulated toxicity are reduced, and the dissolution efficiency and the skin mildness are both considered.

The invention discloses a moxidectin pouring solution and a preparation method thereof, and belongs to the technical field of veterinary drug preparations. Every 500 ml of the moxidectin pouring solution comprises 0.1%-10% of moxidectin, an antioxidant, a penetrating agent, a tackifier, a cosolvent, a coloring agent and the balance of a fat solvent, and preferably, soybean oil is used as the fat solvent. The preparation method comprises the following steps: mixing and dissolving the components according to a specific sequence, filtering and sub-packaging. The moxidectin pouring solution disclosed by the invention has the advantages of low cost, convenience in preparation, good quality stability, no influence on impurity detection and the like, effectively solves a plurality of problems of the moxidectin pouring solution in the prior art, and has a good application prospect.

The invention discloses a temperature-sensitive hydrogel based on Chinese prickly ash alkaloid. The temperature-sensitive hydrogel is prepared from poloxamer 407, poloxamer 188 and Chinese prickly ash alkaloid powder. The temperature-sensitive hydrogel based on the pepper alkaloid prepared by the invention has three characteristics of biological adhesion, self-healing property and slow release property, and solves the technical problems that the pepper alkaloid is poor in stability and uncontrollable in drug release.

The invention discloses a haemonchus contortus subunit vaccine, and belongs to the field of veterinary vaccines. The subunit vaccine comprises an antigen protein MEP3, an antigen protein AP1, an antigen protein AP8, an antigen protein H11-2, an antigen protein H11-4 and an antigen protein AP5 of galactosylated and modified haemonchus contortus, and the antigen protein MEP3, the antigen protein AP1, the antigen protein AP8, the antigen protein H11-2, the antigen protein H11-4 and the antigen protein AP5 of galactosylated and modified haemonchus contortus. The galactosylation modification of the antigen protein is realized by jointly expressing glycosyl transferase HcGALT of haemonchus contortus and one or more of the proteins in eukaryotic cells. The antigen protein modified by galactosylation in the subunit vaccine is closer to the glycosylation modification of natural protein, and can provide effective immune protection after the goat is infected with haemonchus contortus, and the egg laying rate is reduced by 81.43%. The invention lays a foundation for development of haemonchus contortus subunit vaccines, provides an effective technical means for prevention and treatment of the haemonchus contortus subunit vaccines, and has important application value and popularization prospect.

The invention discloses an SaRNA vaccine for echinococcosis as well as a preparation method and application of the SaRNA vaccine. The preparation method of the SaRNA vaccine comprises the following steps: carrying out codon optimization on a modified target antigen protein through a genetic engineering technology, then assembling the modified target antigen protein with a self-replicating protein sequence, 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a plasmid, and carrying out purification to obtain the SaRNA vaccine. The preparation method comprises the following steps: constructing recombinant plasmids, sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmids to prepare SaRNA molecules, and finally wrapping the SaRNA molecules in lipid nanoparticles to form the SaRNA vaccine for the echinococcosis. Experiments prove that the SaRNA vaccine can activate humoral immunity and cellular immunity of mice at the same time, high-level EG95 specific antibodies and cytokines can be generated through low-dose immunity, and the SaRNA vaccine has wide application prospects in the aspect of preventing and / or treating the echinococcosis.

Disclosed are novel pharmaceutical, animal feed compositions and methods of treating non-human animals comprising at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s), or mixtures thereof, derived from non-woody plants of the genus Hesperaloe. Animal feed compositions may comprise a basal animal feed and water soluble solids extracted from Hesperaloe and comprising at least one saponin. The water soluble solids may comprise from about 5 to about 30 wt % saponin. The compositions of the present invention can be used for the treatment of non-human animals, such as poultry and more particularly for preventing and treating coccidiosis. An embodiment provides an immunological composition useful for inducing the production of antibodies to an antigen in a non-human animal comprising an antigen, preferably a coccidia, and a saponin composition extracted from Hesperaloe. The saponins extracted from Hesperaloe biomass may comprise 25(27)-dehydrofucreastatin, 5(6),25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin and yuccaloiside C.

The invention discloses application of ursolic acid in resisting fish ichthyophthiriasis. The ursolic acid has a remarkable killing effect on ichthyophthirius multifilis in an in-vitro stage, and the 4-hour half effective insecticidal concentration (4h-EC50) of the ursolic acid on a grazing body is 0.3774 mg / L; and the 22-hour half effective insecticidal concentration (22h-EC 50) on the capsule is 4.931 mg / L. An acute toxicity test shows that the 96-hour median lethal concentration (96h-LC50) of ursolic acid to goldfish is 9.358 mg / L, the therapeutic index (TI = 96h-LC50 / 4h-EC50) is up to 24.8, and the safety of ursolic acid is remarkably superior to that of a traditional medicine. Ursolic acid used in the invention is a plant-derived active component, has the characteristics of high environmental compatibility and low biological accumulation, meets the development requirements of green fishery, and has an industrialization basis for being developed into eco-friendly aquatic products.

Disclosed herein are compositions which can be used in methods for treating or preventing ophthalmic and dermatologic conditions in a human subject, including ocular surface conditions such as blepharitis or rosacea. The compositions can be topically administered directly to an eye, eyelid, or eyelashes of the patient for targeted local activity.

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

The invention discloses a compound as shown in a formula (I), and / or pharmaceutically acceptable salts thereof, and / or a raceme mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof, and belongs to the technical field of medicines. The invention also discloses a pharmaceutical composition containing the compound as shown in the formula (I), and the compound as shown in the formula (I) and / or a pharmaceutically acceptable salt thereof, and / or a racemic mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof, and / or the pharmaceutical composition, a pharmaceutically acceptable salt thereof, and / or a racemic mixture, a hydrate, a solvate, a prodrug, an enantiomer, a diastereoisomer and a tautomer thereof. The invention further discloses application of the cGAS agonist in preparation of the cGAS agonist and a medicament for treating diseases responding to activation of the cGAS-STING signal channel.

The invention discloses a recombinant subunit vaccine for resisting trichomonas pigeonae infection and a preparation method of the recombinant subunit vaccine. The vaccine comprises two recombinant proteins with sequences as shown in SEQ ID NO: 7 and SEQ ID NO: 8 respectively and a pharmaceutically acceptable carrier. According to the invention, Sf9 cells are used for respectively expressing trichomonas pigeonae adhesion protein 33 and adhesion protein 65, the immunogenicity of the obtained recombinant protein is similar to that of natural protein, the expression level is high, the immunogenicity is strong, a very small amount of recombinant protein can provide a better immune protection effect, and the recombinant protein has no pathogenicity to pigeons, and can be used for preparing the recombinant protein for preventing and treating trichomonas pigeonae. Meanwhile, large-scale serum-free suspension culture can be carried out through a bioreactor, so that the vaccine production cost is greatly reduced.

The invention discloses an antigen fusion protein and application thereof in preparation of a live vaccine for preventing infectious bursal disease. Specifically disclosed are antigen fusion proteins comprising a VP2 protein, a trimer tag, and a C3d protein. The invention also discloses recombinant Eimeria heap constructed by using the antigen fusion protein and application of the recombinant Eimeria heap in preparation of IBDV live vaccines. The oocyst of the recombinant Eimeria heap can effectively induce humoral immune response aiming at IBDV as a vaccine active ingredient, the level of an induced antibody is obviously higher than that of an insect strain expressed by a single VP2 antigen, viruses can be more effectively neutralized, the immune protection efficacy is improved, the safety is high, and the oocyst has the potential of serving as a live vector genetic engineering vaccine. The IBDV live vaccine can be orally taken through drinking water or feed, vaccination is simple, large-scale immunization of chicken flocks can be achieved, and the IBDV live vaccine is economical and efficient and has a wide prospect of being applied to prevention and control of the IBDV of the chicken flocks.

The invention relates to a dihydroartemisinic acid inclusion compound as well as a preparation method and application thereof. The dihydroarteannuic acid clathrate compound comprises dihydroarteannuic acid and a cyclodextrin compound wrapping the dihydroarteannuic acid. The cyclodextrin compound comprises cyclodextrin and / or a cyclodextrin derivative. According to the invention, the inclusion effect of the cyclodextrin compound on the dihydroarteannuic acid is utilized, so that dihydroarteannuic acid molecules are embedded in the tubular structure of the cyclodextrin compound, and the water solubility of the dihydroarteannuic acid is greatly improved.

The invention relates to the field of pet nursing, in particular to citron flower mite-killing pet spray and a preparation method thereof.The citron flower mite-killing pet spray comprises a two-phase release system composed of an immediate release phase and a slow release phase, the immediate release phase is a nano-emulsified citron flower extract and a synergistic plant extract, and the particle size of the immediate release phase is 50-80 nanometers; the slow-release phase is a microencapsulated citron flower extract and a synergistic plant extract, and the particle size is 2-15 microns; the mass ratio of the immediate release phase to the slow release phase of the two-phase system is equal to 40: 60; the mass ratio of the citron flower extract to the synergistic plant extract is 1.5: 1 to 4: 1; the synergistic plant extract is selected from one or more of tea tree oil, green prickleyash extract and lemon eucalyptus leaf extract, and by optimizing the ratio of the citron flower extract to the synergistic plant extract and utilizing the synergistic effect of multiple acaricidal mechanisms, the acaricidal rate can reach 95% or above, and the acaricidal effect is better than that of a single plant extract.

The invention relates to a vaccine for preventing and treating sheep echinococcosis infection and a preparation method thereof.The preparation method comprises the steps that echinococcosis Eg95 full-length gene antigen epitopes are screened through bioinformatics software, screened fragments with high antigenicity are optimized and then subjected to double-copy connection through a flexible linker, His tag sequences are added to the two ends of a tandem sequence, the sequence is as shown in SEQ ID NO.2, and the vaccine for preventing and treating sheep echinococcosis infection is obtained; and the pEE12.4-double Eg95 plasmid is connected with a CHO eukaryotic cell expression vector, so that the pEE12.4-double Eg95 plasmid is obtained. The plasmid is integrated into a CHO eukaryotic cell expression system, the expression quantity of the purified Eg95 protein reaches 10g / L, and a stable and high-yield veterinary vaccine is provided for large-scale production.

The invention discloses an echinococcosis mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application thereof. The preparation method of the mRNA vaccine for the echinococcosis comprises the following steps: carrying out codon optimization on a modified target antigen protein, then assembling the modified target antigen protein with 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a pUC57 plasmid, and sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmid to prepare an mRNA molecule, thereby obtaining the mRNA vaccine for the echinococcosis. Finally, mRNA molecules are wrapped in lipid nanoparticles through a microfluidic method to form the mRNA vaccine for the echinococcosis, and immune effect evaluation is carried out on the mRNA vaccine for the echinococcosis. Experiments prove that the prepared mRNA vaccine for the echinococcosis can activate humoral immunity and cellular immunity of mice at the same time, can provide an effective protection effect for the mice attacking insects, and has a wide application prospect in the aspect of preventing and / or treating the echinococcosis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of bleomycin or bleomycin analogues in preparation of an immunopotentiator. The invention also provides a pharmaceutical composition and application of the pharmaceutical composition in preparation of drugs for treating and / or preventing cancers. The pharmaceutical composition comprises bleomycin, bleomycin analogues or a combination thereof and an anti-tumor immunotherapeutic agent.

The invention discloses an application of brucea javanica bitter alcohol (BRU) in preparation of a medicine for treating malaria. The invention belongs to the technical field of biological medicine. According to the invention, a model that mice are infected with a Plasmodium berghei (Plasmodium berghei, pb) ANKA insect strain and a Plasmodium johnsonii (Plasmodium yoelii, py) 17XNL insect strain is established, and BRU in-vivo insecticidal effect observation is carried out. Observation indexes mainly comprise insect blood rate calculation, anemia condition, liver and kidney function influence, spleen form and insect body ultrastructure detection. Results show that the BRU (as shown in the formula I) has a remarkable effect of killing the plasmodium, and can directly damage the ultrastructure of the plasmodium body, block the development of the plasmodium body and remarkably improve the degree of mouse spleen damage caused by plasmodium infection so as to improve the anemia condition of the mouse. And the influence on liver and kidney functions is slight and reversible. Therefore, a new technical means is provided for malaria treatment, and the brucea javanica bitter alcohol has a wide application prospect in the aspect of treating parasitic infection. # imgabs0 #

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as V-domain immunoglobulin suppressor of T-cell activation (VISTA) inhibitors or as dual inhibitors of VISTA and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA and its ligands, PD-1, PD-L1, and / or PD-L2.

A nanomedicinal composition comprising a nanocarrier and an antioxidant. The nanocarrier contains a metal organic framework and a porous silicate and / or aluminosilicate matrix. The antioxidant is disposed in the pores and / or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating Blastocystis infection.

Compounds of formula I (Formula I),where the substituents R1 through R5 are defined herein, and agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of the compounds of Formula (I). In addition, methods and uses of compounds of Formula I as, for example, insecticides. Compositions having compounds of Formula (I) and their uses in controlling insects, particularly in crops of useful plants. Methods and intermediates related to the synthesis of compounds of Formula (I).

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.

The invention relates to the technical field of microorganisms, in particular to application of butyric acid producing enterobacter as a probiotic for resisting eimeria tenella. In the invention, an antibiotic cocktail-induced eimeria tenella infection model is utilized to explore the effect of butyric acid-producing enterobacter DSM 26588 on eimeria tenella development. The enterobacter butyricum DSM 26588 inhibits the growth of gametes by inhibiting the expression of the eimeria tenella gamete EtGFAT gene; according to the present invention, the intestinal tract lesion caused by Eimeria tenella infection can be improved, the intestinal tract pathological injury can be alleviated so as to reduce the Eimeria tenella oocyst discharge amount, the ACI value is 162, and the good anti-coccidiosis effect can be provided.